Aurinia Pharmaceuticals Inc. Reiterates Guidance for the Full Year 2025

Published: 2025-05-12 06:12:00 ET AUPH

Published on 05/12/2025 at 06:12, updated on 05/12/2025 at 07:05

Aurinia Pharmaceuticals Inc. reiterated earnings guidance for the Full year 2025. For the year, company reiterated its established total revenue guidance in the range of $250 million to $260 million and net product sales guidance in the range of $240 million to $250 million.